« Return to News | Awards & Advancement

Jazz makes management appointments

Monday, January 30, 2012 02:28 PM

Jazz Pharmaceuticals, a biopharmaceutical company specializing in products that address unmet medical needs, has appointed the following individuals to senior management positions:

Suzanne Sawochka Hooper will become general counsel and an executive officer. Hooper is currently a partner at Cooley, where she has practiced corporate and securities law since 1996. She has provided counsel to Jazz Pharmaceuticals for more than five years and was closely involved in the company's recent business combination with Azur Pharma.

Fintan Keegan has been appointed senior vice president of technical operations and will oversee the company's manufacturing, supply chain, quality and technical operations. Keegan was previously with Azur Pharma since 2006. He has over 27 years of experience in manufacturing and related technical operations.

Eunan Maguire will become senior vice president of strategy and corporate development and focus on the company's efforts to expand its product portfolio. Maguire was a co-founder of Azur Pharma and was president of U.S. operations. He has over 15 years of industry experience.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.